![FDA, FTC and DOJ Enforcement of Medical Device Regulations FDA, FTC and DOJ Enforcement of Medical Device Regulations](https://www.fdanews.com/ext/resources/Book-Covers-2/BFFDEMDR-COVER.png?height=200&t=1685733565&width=200)
Home » FDA Pushes Back Comment Period on Hep C Drug Development Guidance
FDA Pushes Back Comment Period on Hep C Drug Development Guidance
![](https://www.fdanews.com/ext/resources/test/Device_Images5/Testtubesonbluebg.gif?t=1474482396&width=430)
The FDA has extended the comment period for its draft guidance for developing direct-acting antiviral hepatitis C drugs to July 19.
The agency attributes the extension to maintenance on the Federal eRulemaking portal from July 1 through July 5.
The draft guidance, which recommended that companies factor in interferon treatment when designing clinical trials, previously was released for comment in May.
Upcoming Events
-
21Oct